The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

Association comprising: dry extract of Bacopa monnieri, Astaxanthin, Vitamin E, L-theanine and dry extract of Centella asiatica for use as an adjuvant in the prevention of vascular dementia, as it is able to reduce the main modifiable risk factors of cognitive vascular impairment (VCI).

Association comprising: dry extract of Bacopa monnieri, Astaxanthin, Vitamin E, L-theanine and dry extract of Centella asiatica for use as an adjuvant in the prevention of vascular dementia, as it is able to reduce the main modifiable risk factors of cognitive vascular impairment (VCI).

Association comprising: dry extract of Bacopa monnieri, Astaxanthin, Vitamin E, L-theanine and dry extract of Centella asiatica for use as an adjuvant in the prevention of vascular dementia, as it is able to reduce the main modifiable risk factors of cognitive vascular impairment (VCI).

The present invention relates to diagnosing, preventing, delaying or reverting the progression of pathologies associated with abnormal amyloid deposits, such as that exemplified by Alzheimer's disease (AD). More specifically, the method involves administration of specific molecules that function as Piezo agonists, such as Yoda1, Jedi1, 5 Jedi2, or functional analogs thereof, that are able to modulate microglial activation towards anti-inflammatory state and/or interfere with the formation of amyloidogenic peptides and/or increase their efflux from the central nervous system. These agonists are applicable in disease states associated with, or at risk of, cerebral amyloidosis, such as AD, Parkinson's disease, stroke, head trauma(s), cerebral amyloid angiopathies, spongiform 10 encephalopathies and scrapie all of which are evidenced with abnormal proinflammatory microglial activation

The present invention relates to diagnosing, preventing, delaying or reverting the progression of pathologies associated with abnormal amyloid deposits, such as that exemplified by Alzheimer's disease (AD). More specifically, the method involves administration of specific molecules that function as Piezo agonists, such as Yoda1, Jedi1, 5 Jedi2, or functional analogs thereof, that are able to modulate microglial activation towards anti-inflammatory state and/or interfere with the formation of amyloidogenic peptides and/or increase their efflux from the central nervous system. These agonists are applicable in disease states associated with, or at risk of, cerebral amyloidosis, such as AD, Parkinson's disease, stroke, head trauma(s), cerebral amyloid angiopathies, spongiform 10 encephalopathies and scrapie all of which are evidenced with abnormal proinflammatory microglial activation

Water-soluble, cell-permeable nanomicelles containing ceramides and a steviol glycoside, such as rubusoside, are disclosed. The ceramide-steviol glycoside complex has high water solubility, and can be used for treating cancers with p53 mutations. Preliminary results have shown that the Cer nanomicelles are effective in restoring p53 protein expression, and that they are functionally dominant over p53 mutants. The novel nanomicelles restore a wild-type phenotype, and have very low toxicity to noncancerous cells. The novel Cer nanomicelles may be used in treating p53-associated cancers.